Literature DB >> 5724877

Immune response with particular reference to the use of multiple antigens.

P F Wehrle.   

Abstract

The increasing demand for preventive child health services and the general increase in international travel compel greater attention to the use of multiple antigens, both inactivated and live, when administered simultaneously. It appears that with the preparations currently licensed, multiple inactivated antigens may be given safely and with expectation of optimal effectiveness. dpt is a routine combination employed in combination with oral trivalent poliovaccine for primary immunization of infants and young children up to and including age six. Oral poliovirus vaccine and vaccinia may be administered at the time of the recall or booster dose of dpt vaccine during the second year of life, commonly at age 15 to 18 months. It is apparent from published data accumulated over many years that several antigens may be administered at the same time with adequate immunologic response. The minor differences in antibody response following simultaneous administration of live viral antigens is of unknown clinical importance. The primary reason for hesitancy in advocating greater use of multiple agents at this time is the theoretical consideration of possible neurotoxicity with those vaccines where the parent agent may have definite neurotoxicity. The question of possible additive or other harmful effects with measles, poliomyelitis, and rubella and mumps when given simultaneously can be answered only by carefully controlled studies involving close observation of the recipients with extension of these trials as data permit.

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 5724877      PMCID: PMC1503384     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  27 in total

1.  SIMULTANEOUS ADMINISTRATION OF ORAL POLIO VACCINE AND GLOBULIN-MODIFIED ATTENUATED MEASLES-VIRUS VACCINE.

Authors:  J E FROESCHLE; H CASEY
Journal:  J Pediatr       Date:  1965-06       Impact factor: 4.406

2.  CIRCULATING INTERFERON AFTER MEASLES VACCINATION.

Authors:  J K PETRALLI; T C MERIGAN; J R WILBUR
Journal:  N Engl J Med       Date:  1965-07-22       Impact factor: 91.245

3.  CIRCULATING VIRUS, INTERFERON AND ANTIBODY AFTER VACCINATION WITH THE 17-D STRAIN OF YELLOW-FEVER VIRUS.

Authors:  E F WHEELOCK; W A SIBLEY
Journal:  N Engl J Med       Date:  1965-07-22       Impact factor: 91.245

4.  Some factors influencing the response to immunisation with single and combined prophylactics.

Authors:  M BARR; M LLEWELLYN-JONES
Journal:  Br J Exp Pathol       Date:  1955-04

5.  Quantitative studies in diphtheria prophylaxis. Antigenic interactions. I. Simultaneous inoculations.

Authors:  J M BARNES; L B HOLT
Journal:  Br J Exp Pathol       Date:  1955-08

6.  Reinoculation with multiple antigen preparations of free-living children previously inoculated with multiple antigen preparations.

Authors:  V K VOLK; F H TOP; W E BUNNEY
Journal:  Am J Public Health Nations Health       Date:  1953-07

7.  Interference with antitoxic responses in immunisation with combined prophylactics.

Authors:  M BARR; M LLEWELLYN-JONES
Journal:  Br J Exp Pathol       Date:  1953-06

8.  Standardization and mass application of combined live measles-smallpox vaccine in Upper Volta.

Authors:  F Kalabus; H Sansarricq; P Lambin; J Proulx; M R Hillman
Journal:  Am J Epidemiol       Date:  1967-07       Impact factor: 4.897

9.  Simultaneous administration of live measles virus vaccine and smallpox vaccine.

Authors:  P M Sherman; R G Hendrickse; D Montefiore; T Peradze; G Coker
Journal:  Br Med J       Date:  1967-06-10

10.  The carriage of immunological memory by small lymphocytes in the rat.

Authors:  J L Gowans; J W Uhr
Journal:  J Exp Med       Date:  1966-11-01       Impact factor: 14.307

View more
  1 in total

1.  MMR Vaccine: When Is the Right Time for the Second Dose?

Authors:  Oscar R Herrera; Terrika A Thornton; Richard A Helms; Stephan L Foster
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Mar-Apr
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.